Multiparticles safeguarded against ethanolic dose-dumping

• US 9,872,835 B2
• Filed: 05/22/2015
• Issued: 01/23/2018
• Est. Priority Date: 05/26/2014
• Status: Expired due to Fees

• Current Assignee: Grunenthal GMBH (Grünenthal Pharma GmbH & Co. KG)
• Original Assignee: Grunenthal GMBH (Grünenthal Pharma GmbH & Co. KG)
• Inventors: Barnscheid, Lutz, Wening, Klaus, Ptz, Jana, Geissler, Anja
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US14/719,351
• Publication Number:
  US 20150335592A1
• Time in Patent Office: 977 Days
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 9/1623 Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/1682 Processes
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to an oral pharmaceutical dosage form providing resistance against dose dumping in aqueous ethanol and comprising a pharmacologically active ingredient embedded in a matrix material,

• • wherein the matrix material comprises an alkyl cellulose and a heteropolysaccharide; and
  • wherein the relative weight ratio of heteropolysaccharide to alkyl cellulose is within the range of from 1:20 to 20:1; and
    wherein the total content of alkyl cellulose and heteropolysaccharide is at least 35 wt.-%, relative to the total weight of the dosage form. A process of producing the dosage form and methods of using the dosage form, for example to treat pain, are also disclosed.

Claims

1. An oral pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a matrix material, wherein:

the pharmacologically active ingredient is one selected from pharmacologically active ingredients classified in Anatomical Therapeutic Chemical Classification System (ATC), class Nervous System;

the matrix material comprises a mixture of an alkyl cellulose and a heteropolysaccharide;

the alkyl cellulose is present in the dosage form in an amount of at least 50 wt.-% relative to the total weight of the dosage form;

the heteropolysaccharide is present in the dosage form in an amount of below 50 wt.-% relative to the total weight of the dosage form;

the total content of alkyl cellulose and heteropolysaccharide is at least 60 wt.-% relative to the total weight of the dosage form;

the pharmaceutical dosage form releases by 60 minutes more than 60% of the pharmacologically active ingredient when release of the pharmacologically active ingredient from the pharmaceutical dosage form is measured with a paddle apparatus at 50 rpm, at 37±

5°

C., in 900 mL 0.1 M HCl (pH 1.0) or simulated intestinal fluid at pH 6.8 (phosphate buffer) or pH 4.5; and

the pharmaceutical dosage form provides resistance against dose dumping in aqueous ethanol.

2. The dosage form according to claim 1, wherein

the alkyl cellulose is ethyl cellulose;

and/or

the heteropolysaccharide is xanthan gum.

3. The dosage form according to claim 1, which provides prolonged release of the pharmacologically active ingredient.

4. The dosage form according to claim 1, wherein the content of the heteropolysaccharide is below 45 wt.-%, relative to the total weight of the dosage form.

5. The dosage form according to claim 4, wherein the content of the heteropolysaccharide is below 30 wt.-%, relative to the total weight of the dosage form.

6. The dosage form according to claim 1, wherein the total content of alkyl cellulose and heteropolysaccharide is at least 70 wt.-%, relative to the total weight of the dosage form.

7. The dosage form according to claim 1, wherein the alkyl cellulose is ethyl cellulose having an ethoxyl content of from 40 wt.-% to 60 wt.-%.

8. The dosage form according to claim 1, wherein the alkyl cellulose is ethyl cellulose having a solution viscosity within the range of from 70 mPa·

s to 130 mPa·

s, measured in a 5 wt.-% solution of 80 wt.-% toluene and 20 wt.-% ethanol at 25°

C. in an Ubbelohde viscosimeter.

9. The dosage form according to claim 1, wherein the pharmacologically active ingredient is an opioid.

10. The dosage form according to claim 9, wherein the pharmacologically active ingredient is selected from the group consisting of oxycodone, oxymorphone, hydrocodone, hydromorphone, tramadol, tapentadol, morphine, buprenorphine, and the physiologically acceptable salts thereof.

11. The dosage form according to claim 1, which is particulate.

12. The dosage form according to claim 1, which is a filled capsule or a tablet.

13. The dosage form according to claim 1, which is particulate and in form of a filled capsule, wherein

the pharmacologically active ingredient is selected from the group consisting of oxycodone, oxymorphone, hydrocodone, hydromorphone, tramadol, tapentadol, morphine, buprenorphine, and the physiologically acceptable salts thereof;

and

the alkyl cellulose is ethyl cellulose; and

the heteropolysaccharide is xanthan gum; and

the relative weight ratio of xanthan gum to ethyl cellulose is within the range of from 1;

18 to 1;

1.

14. A method for treating pain in a patient in need thereof, said method comprising administering to said patient an effective amount therefor of a dosage form according to claim 1.

15. The dosage form according to claim 1, wherein the content of the alkyl cellulose is at least 63 wt.-%, relative to the total weight of the dosage form.

16. The dosage form according to claim 1, which releases by 3 hours at least 90% of the pharmacologically active ingredient.